Navigation Links
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Date:4/15/2009

rently in Phase 3 development for the treatment of Alzheimer's disease (AD) and in clinical development for Huntington's disease (HD). In preclinical models of AD and HD explored thus far, Dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The Dimebon mechanism is thought to be distinct from currently available AD medications.

Design of the CONCERT Study

The international, randomized, double-blind, placebo-controlled study will enroll approximately 1,050 patients with mild-to-moderate AD at approximately 100 sites in the United States, Australia, New Zealand and Western Europe. Patients on a stable dose of donepezil will be randomized to one of three treatment groups: Dimebon 20 mg three times per day, Dimebon 5 mg three times per day or placebo. Patients must be on treatment with donepezil for at least six months and at a stable dose of 10 mg daily for at least four months prior to enrollment in the study.

The primary endpoints are the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) - a measure of self-care and daily function.

For more information on the CONCERT study, please visit www.concertstudy.com or call 877-888-6386.

About Alzheimer's Disease

Alzheimer's disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations.

About the Pfizer/Medivation Dimebon Collabor
'/>"/>

SOURCE Pfizer Inc; Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
2. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. MannKind Addresses Pfizers Announcement Regarding Exubera
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
9. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
10. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Sihuan Pharmaceutical Holdings ... "Company"), a leading pharmaceutical company with the largest ... China,s prescription drug market, today announced ... its subsidiaries (collectively the "Group") for the six ... Financial HighlightsFor the Six months ended 30 ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver ... on the Fatty Liver Disease clinical trial scenario. This ... clinical trials on Fatty Liver Disease . It ... recruitment status as per the site of trial conduction ... of disease clinical trials by their phase, trial status, ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
(Date:8/28/2014)... (PRWEB) August 28, 2014 Now in its ... that was started in 2011 by two brain aneurysm survivors. ... much needed awareness, provide education to help increase early detection ... impacted by a brain aneurysm. We hope that you will ... worthy cause at the 4th Annual Step for Hope Run/ ...
(Date:8/28/2014)... MMAR Medical is pleased to announce ... for regular customers to enjoy several perks and benefits ... a wholesale license. It’s a great choice for independent ... others who regularly purchase medical braces but could use ... own active lifestyle or those of your club, group ...
(Date:8/28/2014)... The revenue cycle process touches on ... time a patient books an appointment with a physician’s ... payments for services rendered to the healthcare provider. ... has the RCM process down to a science. Over ... common place in nearly every healthcare facility around the ...
(Date:8/28/2014)... August 28, 2014 UniVoIP, Inc, a ... Segundo, CA, today announced that they have been certified ... Los Angeles Local Small Business Enterprise (Local SBE) Preference ... certified by the state of California and LA county ... Cloud-hosted Telephony Solution to governmental agencies throughout the ...
(Date:8/27/2014)... 2014 Author and orthopedic surgeon William ... on the thrilling adventures of sharp and witty ... is gearing up for a new marketing push in ... novellas , “Prescription: Murder” follows the adventures of ... dodging assassination attempts and thwarting criminals. In the first ...
Breaking Medicine News(10 mins):Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:MMAR Medical Announces Customer Membership Program 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Cloud PBX Provider UniVoIP Gets Certified by the State of California and the County of Los Angeles Under the Local Small Business Enterprise (SBE) Preference Program 2Health News:William H. Simon Launches New Marketing Campaign for Book 2
... - Sunrise Senior Living and Conrad Properties Partner to Redefine Landmark ... Property Exclusively For Seniors ... SRZ ), an operator of more than 450 senior living communities,worldwide, ... 23- story Clayton on the Park hotel and apartments into an,exclusive ...
... entire Texas,Medical Board (TMB) and its officials have been ... Physicians and Surgeons (AAPS). The complaint,filed this week in ... performing its official duties, specifically:, 1. Manipulation of ... Violation of due process;, 4. Breach of privacy; ...
... Virginia, Dec. 21 Echo Healthcare,Acquisition Corp. ("Echo" ... check company, announced at its special meeting of ... Friday, December 28, 2007 for,stockholders to vote on ... ("XLNT") and the related matters set forth in ...
... Pa. and KENILWORTH, N.J., Dec. 21 ,Centocor, ... ) today announced,they have revised their 1998 ... of both REMICADE(R),(infliximab), an anti-tumor necrosis factor ... golimumab, Centocor,s next-generation,human, anti-TNF alpha therapy, which ...
... will ensure consumers, interests are considered, protected, HARRISBURG, ... are protected, acting Insurance Commissioner Joel,Ario today announced that ... part of its review of the proposed consolidation of,Independence ... is to see that consumers would be protected in,any ...
... team says , FRIDAY, Dec. 21 (HealthDay News) -- People with ... a study that adds to growing evidence of a link between ... analyzed leg and torso measurements, as well as blood samples, from ... , The blood samples were checked for levels of four liver ...
Cached Medicine News:Health News:Sunrise to Unveil New Residence for Seniors at Clayton on the Park 2Health News:Doctors' Group Sues Texas Medical Board for Misconduct; Cites Institutional Culture of Retaliation & Intimidation 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 2Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 4Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2Health News:Shorter Legs Might Boost Liver Risks 2
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: